PinnyPeptide

Crystagen vs Vesilute

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Crystagen

Bioregulators

Khavinson short peptide bioregulator targeting thymus / immune cells.

Peptide B

Vesilute

Bioregulators

Khavinson short peptide bioregulator targeting urinary bladder epithelium.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Crystagen effects

  • Reported improvement in T-cell numbers and function
  • Restoration of age-related immune decline (Russian observational)
  • Support of thymic function in elderly patients
  • Anti-inflammatory effects
  • Recovery support after severe illness

Vesilute effects

  • Reported improvement in chronic cystitis symptoms
  • Possible reduction in overactive bladder symptoms
  • Anti-inflammatory effects in bladder tissue
  • Support of bladder epithelial integrity
  • Modulation of bladder gene expression

Crystagen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Theoretical: caution in active autoimmune disease (immune modulation)

Vesilute side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Not a substitute for proper urological evaluation

Crystagen dosing ranges

Immune support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Vesilute dosing ranges

Bladder function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Crystagen guide → Full Vesilute guide →

Crystagen vs Vesilute — common questions

What is the difference between Crystagen and Vesilute?

Crystagen: Khavinson short peptide bioregulator targeting thymus / immune cells. Typical dose 1,000-5,000 mcg. Vesilute: Khavinson short peptide bioregulator targeting urinary bladder epithelium. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Crystagen and Vesilute?

Stacking Crystagen with Vesilute is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Crystagen or Vesilute?

Crystagen is typically dosed: Once daily (SubQ) or sublingual for Immune support. Vesilute is typically dosed: Once daily (SubQ) or sublingual for Bladder function support.

Are Crystagen and Vesilute FDA approved?

Crystagen: Not FDA approved. Vesilute: Not FDA approved.

Related peptide comparisons

bronchogen vs crystagencardiogen vs crystagencartalax vs crystagencortagen vs crystagencrystagen vs ovagencrystagen vs pancragen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free